U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H18N4O3
Molecular Weight 290.3177
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRIMETHOPRIM

SMILES

COC1=CC(CC2=C(N)N=C(N)N=C2)=CC(OC)=C1OC

InChI

InChIKey=IEDVJHCEMCRBQM-UHFFFAOYSA-N
InChI=1S/C14H18N4O3/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15/h5-7H,4H2,1-3H3,(H4,15,16,17,18)

HIDE SMILES / InChI

Molecular Formula C14H18N4O3
Molecular Weight 290.3177
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Trimethoprim (TMP) is an antibiotic is used for the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Enterobacter species, and coagulase-negative Staphylococcus species, including S. saprophyticus. Cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. Therapy may be initiated prior to obtaining the results of these tests. Trimethoprim is rapidly absorbed following oral administration. It exists in the blood as unbound, protein-bound, and metabolized forms. Ten to twenty percent of trimethoprim is metabolized, primarily in the liver; the remainder is excreted unchanged in the urine. The principal metabolites of trimethoprim are the 1- and 3-oxides and the 3'- and 4'-hydroxy derivatives. The free form is considered to be the therapeutically active form. Approximately 44% of trimethoprim is bound to plasma proteins. Trimethoprim blocks the production of tetrahydrofolic acid from dihydrofolic acid by binding to and reversibly inhibiting the required enzyme, dihydrofolate reductase. This binding is very much stronger for the bacterial enzyme than for the corresponding mammalian enzyme

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
TRIMETHOPRIM

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of trimethoprim tablets, USP and other antibacterial drugs, trimethoprim tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. For the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Enterobacter species, and coagulase-negative Staphylococcus species, including S. saprophyticus. Cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. Therapy may be initiated prior to obtaining the results of these tests.

Launch Date

3.96748784E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2.1 μg/mL
2 g single, oral
dose: 2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
TRIMETHOPRIM plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE
food status: UNKNOWN
1 μg/mL
1 g single, oral
dose: 1 g
route of administration: Oral
experiment type: SINGLE
co-administered:
TRIMETHOPRIM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
30.7 μg × h/mL
2 g single, oral
dose: 2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
TRIMETHOPRIM plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
10 h
1 g single, oral
dose: 1 g
route of administration: Oral
experiment type: SINGLE
co-administered:
TRIMETHOPRIM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
56%
1 g single, oral
dose: 1 g
route of administration: Oral
experiment type: SINGLE
co-administered:
TRIMETHOPRIM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
300 mg 2 times / day multiple, oral
Highest studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: severe shigellosis
Sources:
1 g 1 times / day multiple, oral
Overdose
Dose: 1 g, 1 times / day
Route: oral
Route: multiple
Dose: 1 g, 1 times / day
Sources:
unhealthy
Other AEs: Nausea, Vomiting...
Other AEs:
Nausea
Vomiting
Dizziness
Headaches
Confusion
Bone marrow depression
Sources:
AEs

AEs

AESignificanceDosePopulation
Bone marrow depression
1 g 1 times / day multiple, oral
Overdose
Dose: 1 g, 1 times / day
Route: oral
Route: multiple
Dose: 1 g, 1 times / day
Sources:
unhealthy
Confusion
1 g 1 times / day multiple, oral
Overdose
Dose: 1 g, 1 times / day
Route: oral
Route: multiple
Dose: 1 g, 1 times / day
Sources:
unhealthy
Dizziness
1 g 1 times / day multiple, oral
Overdose
Dose: 1 g, 1 times / day
Route: oral
Route: multiple
Dose: 1 g, 1 times / day
Sources:
unhealthy
Headaches
1 g 1 times / day multiple, oral
Overdose
Dose: 1 g, 1 times / day
Route: oral
Route: multiple
Dose: 1 g, 1 times / day
Sources:
unhealthy
Nausea
1 g 1 times / day multiple, oral
Overdose
Dose: 1 g, 1 times / day
Route: oral
Route: multiple
Dose: 1 g, 1 times / day
Sources:
unhealthy
Vomiting
1 g 1 times / day multiple, oral
Overdose
Dose: 1 g, 1 times / day
Route: oral
Route: multiple
Dose: 1 g, 1 times / day
Sources:
unhealthy
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
strong [IC50 32 uM]
yes (co-administration study)
Comment: selective inhibition; Trimethoprim raised the AUC(0,∞) and Cmax of repaglinide by 61% (range, 30–117%; P = 0.0008) and 41% (P = 0.005), respectively; Although there was no detectable increase in the effect of repaglinide on blood glucose at the doses used, an enhanced risk of hypoglycaemia during concomitant use of trimethoprim and repaglinide is a possibility
Page: 4.0
yes [IC50 1318 uM]
yes [Inhibition 250 uM]
yes [Inhibition 250 uM]
yes [Inhibition 250 uM]
yes [Inhibition 250 uM]
yes [Inhibition <250 uM]
yes [Inhibition <250 uM]
Drug as victim
PubMed

PubMed

TitleDatePubMed
Synthesis and biological evaluation of 5-arylfuro[2,3-d]pyrimidines as novel dihydrofolate reductase inhibitors.
1999 Feb
Identification of Cryptosporidium parvum dihydrofolate reductase inhibitors by complementation in Saccharomyces cerevisiae.
2000 Apr
Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs.
2000 Jan 14
The pro-apoptotic Bcl-2 family member tBid localizes to mitochondrial contact sites.
2001
The VISA/GISA problem: therapeutic implications.
2001
[Whipple disease and non-Hodgkin lymphoma].
2001 Apr
HIV and drug allergy.
2001 Aug
Predominance of a methicillin-resistant Staphylococcus aureus clone susceptible to erythromycin and several other non-beta-lactam antibiotics in a Greek hospital.
2001 Aug
Antimicrobial resistance of Shigella spp isolated from diarrheal patients between 1989 and 1998 in Vietnam.
2001 Dec
Co-trimoxazole resistant Brucella.
2001 Feb
Bsoft: image and molecular processing in electron microscopy.
2001 Feb-Mar
Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics.
2001 Jan
Travel-associated Burkholderia pseudomallei infection (Melioidosis) in a patient with cystic fibrosis: a case report.
2001 Jan
[Antimicrobial therapy of urinary tract infections].
2001 Jan-Feb
Infectious complications in chronic lymphoid malignancy.
2001 Jun
Antimicrobial sensitivity of Haemophilus influenzae isolates from bacterial conjunctivitis.
2001 Jun
Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area.
2001 Mar
Co-trimoxazole and genital ulceration.
2001 Mar
Changing pattern of biotypes, phage types & drug resistance of Salmonella typhi in Ludhiana during 1980-1999.
2001 May
Effect of early chemoprophylaxis with co-trimoxazole on nutritional status evolution in HIV-1-infected adults in Abidjan, Côte d'Ivoire.
2001 May 4
Epidemiology of major respiratory pathogens.
2001 Nov
Susceptibility patterns and serotypes of non-typhoidal salmonella in Trinidad.
2001 Oct
Bacterial aetiology and anti-microbial resistance of childhood diarrhoea in Yemen.
2001 Oct
Use of systemic anti-infective agents in Iran during 1997-1998.
2001 Sep
Occurrence of enteric redmouth disease in rainbow trout (Oncorhynchus mykiss) on farms in Croatia.
2002
Burkholderia pseudomallei: abscess in an unusual site.
2002 Apr-Jun
Pneumocystis carinii: where are we now?
2002 Feb
A double-hand transplant can be worth the effort!
2002 Jul 15
Modified antimicrobial disc susceptibility testing for nutritionally-variant streptococci.
2002 Mar
The relation between sale of antimicrobial drugs and antibiotic resistance in uropathogens in general practice.
2002 Mar
A European study on the relationship between antimicrobial use and antimicrobial resistance.
2002 Mar
Clinical signs and symptoms in the assessment of immunodeficiency in men with subtype C HIV infection in Harare, Zimbabwe.
2002 Mar-Apr
Urinary tract-derived Escherichia coli resistant to co-trimoxazole in Japan, where the drug is seldom used for treating acute urinary tract infections.
2002 May
Neutropenic enterocolitis (typhlitis) after pediatric bone marrow transplant.
2002 May
Patents

Sample Use Guides

The usual oral adult dosage is 100 mg of trimethoprim every 12 hours or 200 mg of trimethoprim every 24 hours, each for 10 days. The use of trimethoprim in patients with a creatinine clearance of less than 15 mL/min is not recommended. For patients with a creatinine clearance of 15 to 30 mL/min, the dose should be 50 mg every 12 hours.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: Trimethoprim can be used as an alternative to trimethoprim/sulfamethoxazole based on in vitro antibacterial susceptibility.
In vitro susceptibility of bacterial isolates to sulfamethoxazole, trimethoprim and trimethoprim/sulfamethoxazole was determined using disk diffusion. E. coli susceptibility to trimethoprim was 70%, comparable to the 70% of trimethoprim/sulfamethoxazole (p = 0.9)and higher than the 56.9% of sulfamethoxazole (p <0.05).
Substance Class Chemical
Created
by admin
on Thu Jul 06 11:00:12 UTC 2023
Edited
by admin
on Thu Jul 06 11:00:12 UTC 2023
Record UNII
AN164J8Y0X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TRIMETHOPRIM
EP   GREEN BOOK   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
TRIMETHOPRIM COMPONENT OF SULFAMETHOPRIM
Common Name English
TRIMETHOPRIM COMPONENT OF BACTRIM
Common Name English
NIH-204
Code English
SULMEPRIM COMPONENT TRIMETHOPRIM
Common Name English
BACTRIM DS COMPONENT TRIMETHOPRIM
Common Name English
trimethoprim [INN]
Common Name English
2,4-PYRIMIDINEDIAMINE, 5-((3,4,5-TRIMETHOXYPHENYL)METHYL)-
Systematic Name English
NSC-106568
Code English
BACTRIM PEDIATRIC COMPONENT TRIMETHOPRIM
Common Name English
SEPTRA COMPONENT TRIMETHOPRIM
Common Name English
TRIMETHOPRIM COMPONENT OF SEPTRA
Common Name English
WELLCOPRIM
Common Name English
Co-trimoxazole component trimethoprim
Common Name English
TRIMETHOPRIM [HSDB]
Common Name English
TRIMETHOPRIM COMPONENT OF COTRIM
Common Name English
TRIMETHOPRIM COMPONENT OF UROPLUS
Common Name English
COTRIM D.S. COMPONENT TRIMETHOPRIM
Common Name English
TRIMETHOPRIM COMPONENT OF COTRIM D.S.
Common Name English
TRIMETHOPRIM COMPONENT OF BACTRIM PEDIATRIC
Common Name English
TRIMETHOPRIM [VANDF]
Common Name English
TRIMETHOPRIM [USAN]
Common Name English
BW-56-72
Code English
TRIMETHOPRIMUM [WHO-IP LATIN]
Common Name English
TRIMETHOPRIM [USP MONOGRAPH]
Common Name English
SULFATRIM COMPONENT TRIMETHOPRIM
Common Name English
TRIMETHOPRIM [JAN]
Common Name English
SULFAMETHOPRIM COMPONENT TRIMETHOPRIM
Common Name English
TRIMETHOPRIM COMPONENT OF SULFATRIM
Common Name English
TRIMPEX
Brand Name English
TRIMETHOPRIM [ORANGE BOOK]
Common Name English
PROLOPRIM
Brand Name English
TRIMETHOPRIM [MART.]
Common Name English
TMP
Common Name English
TRIMETHOPRIM [EP IMPURITY]
Common Name English
Trimethoprim [WHO-DD]
Common Name English
TRIMETHOPRIM [GREEN BOOK]
Common Name English
BACTRIM COMPONENT TRIMETHOPRIM
Common Name English
TRIMETHOPRIM COMPONENT OF SULMEPRIM
Common Name English
TRIMETHOPRIM [MI]
Common Name English
COTRIM COMPONENT TRIMETHOPRIM
Common Name English
BW 56-72
Code English
TRIMETHOPRIM COMPONENT OF BACTRIM DS
Common Name English
TRIMETHOPRIM [USP-RS]
Common Name English
INFECTOTRIMET
Common Name English
UROPLUS COMPONENT TRIMETHOPRIM
Common Name English
2,4-Diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine
Systematic Name English
TRIMETHOPRIM [EP MONOGRAPH]
Common Name English
Classification Tree Code System Code
WHO-ATC J01EE07
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
CFR 21 CFR 520.2611
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
WHO-VATC QJ01EW09
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
WHO-VATC QJ01EW18
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
WHO-VATC QJ01EW13
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
WHO-ATC J04AM08
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
NDF-RT N0000175489
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
LIVERTOX NBK547937
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
WHO-VATC QJ01EW30
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 6.2.2 (SUL/TRI)
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
WHO-VATC QJ01EW12
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 6.2.2
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
WHO-VATC QJ01EW11
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
WHO-VATC QJ01EW17
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
WHO-VATC QJ01EW16
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
WHO-ATC J01EE03
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
CFR 21 CFR 520.2610
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 6.5.4 (SUL/TRI)
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
WHO-VATC QJ01EW10
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
WHO-ATC J01EE05
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
NCI_THESAURUS C255
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
WHO-ATC J01EE02
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
WHO-ATC J01EE01
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
NDF-RT N0000000191
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
WHO-VATC QJ01EW15
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
WHO-VATC QJ01EA01
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
CFR 21 CFR 522.2610
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
WHO-VATC QJ01EW03
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
WHO-ATC J01EA01
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
WHO-VATC QJ01EW14
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
WHO-VATC QJ51RE01
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
WHO-VATC QJ51EA01
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
WHO-ATC J01EE04
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
CFR 21 CFR 520.2613
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
NDF-RT N0000000191
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
CFR 21 CFR 520.2612
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
Code System Code Type Description
RS_ITEM_NUM
1692505
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
PRIMARY
LACTMED
Trimethoprim
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
PRIMARY
NDF-RT
N0000187061
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
PRIMARY Organic Cation Transporter 2 Inhibitors [MoA]
INN
1047
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
TRIMETHOPRIM
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
PRIMARY Description: A white, crystalline powder; odourless or almost odourless. Solubility: Sparingly soluble in water; soluble in methanol R; practically insoluble in ether R. Category: Antibacterial. Storage: Trimethoprim should be kept in a well-closed container. Definition: Trimethoprim contains not less than 98.5% and not more than 101.0% of C14H18N4O3, calculated with reference to the dried substance.
FDA UNII
AN164J8Y0X
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
PRIMARY
MESH
D014295
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
PRIMARY
MERCK INDEX
M11148
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
PRIMARY Merck Index
WIKIPEDIA
TRIMETHOPRIM
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
PRIMARY
NDF-RT
N0000187062
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
PRIMARY Cytochrome P450 2C8 Inhibitors [MoA]
DRUG CENTRAL
2755
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
PRIMARY
RXCUI
10829
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
PRIMARY RxNorm
NCI_THESAURUS
C908
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
PRIMARY
PUBCHEM
5578
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
PRIMARY
DAILYMED
AN164J8Y0X
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
PRIMARY
CAS
738-70-5
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
PRIMARY
EPA CompTox
DTXSID3023712
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
PRIMARY
NSC
106568
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
PRIMARY
LACTMED
Trimethoprim-Sulfamethoxazole
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
PRIMARY
ECHA (EC/EINECS)
212-006-2
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
PRIMARY
SMS_ID
100000092388
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
PRIMARY
EVMPD
SUB11310MIG
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
PRIMARY
DRUG BANK
DB00440
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
PRIMARY
ChEMBL
CHEMBL22
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
PRIMARY
HSDB
6781
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
PRIMARY
CHEBI
45924
Created by admin on Thu Jul 06 11:00:13 UTC 2023 , Edited by admin on Thu Jul 06 11:00:13 UTC 2023
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
USP
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TARGET ORGANISM->INHIBITOR
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
MAJOR
TARGET -> INHIBITOR
METABOLIC ENZYME -> INHIBITOR
MAJOR
Ki
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
Related Record Type Details
METABOLITE -> PARENT
METABOLITE -> PARENT
Several heterologously expressed P450 enzymes, including CYP1A1, CYP1B1, CYP2C19, CYP3A4, CYP3A5, and CYP3A7, were capable of catalyzing 1-NO-TMP formation
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
CYP1A1 and CYP1B1 were the heterologously expressed enzymes that catalyzed the highest rates of 3-NO-TMP formation.
Related Record Type Details
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
EP
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC